Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OBIO
stocks logo

OBIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
694.00K
+174.31%
-0.372
-13.49%
918.00K
+5.76%
-0.393
-19.9%
932.00K
+11.48%
-0.370
-26%
Estimates Revision
The market is revising Upward the revenue expectations for Orchestra BioMed Holdings, Inc. (OBIO) for FY2025, with the revenue forecasts being adjusted by 3.76% over the past three months. During the same period, the stock price has changed by 70.18%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.76%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.43%
In Past 3 Month
Stock Price
Go Up
up Image
+70.18%
In Past 3 Month
Wall Street analysts forecast OBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OBIO is 12.50 USD with a low forecast of 10.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast OBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OBIO is 12.50 USD with a low forecast of 10.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.680
sliders
Low
10.00
Averages
12.50
High
15.00
Current: 4.680
sliders
Low
10.00
Averages
12.50
High
15.00
Barclays
Overweight
downgrade
$12 -> $11
2025-11-12
Reason
Barclays
Price Target
$12 -> $11
2025-11-12
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Orchestra BioMed to $11 from $12 and keeps an Overweight rating on the shares. The firm says the company highlighted clinical and strategic achievements when reporting Q3.
H.C. Wainwright
Yi Chen
Buy
downgrade
$12 -> $10
2025-09-04
Reason
H.C. Wainwright
Yi Chen
Price Target
$12 -> $10
2025-09-04
downgrade
Buy
Reason
H.C. Wainwright analyst Yi Chen lowered the firm's price target on Orchestra BioMed to $10 from $12 and keeps a Buy rating on the shares. The firm cites increased shares post the company's recent financings for the target cut. However, it believes recenly published data demonstrate the utility of AVIM therapy in lowering blood pressure and improving cardiac function.
BTIG
Buy -> Neutral
downgrade
2025-08-20
Reason
BTIG
Price Target
2025-08-20
downgrade
Buy -> Neutral
Reason
BTIG downgraded Orchestra BioMed to Neutral from Buy without a price target. The firm cites the company's recent dilutive equity financing while maintaining its pace of spending for the downgrade. The funding reduces Orchestra's future profitability while its key catalyst timelines have slipped over the past several quarters, the analyst tells investors in a research note.
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$20
2025-04-22
Reason
Chardan Capital
Keay Nakae
Price Target
$20
2025-04-22
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$14 → $12
2025-04-04
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$14 → $12
2025-04-04
Maintains
Strong Buy
Reason
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$20
2025-04-01
Reason
Chardan Capital
Keay Nakae
Price Target
$20
2025-04-01
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Orchestra Biomed Holdings Inc (OBIO.O) is -2.94, compared to its 5-year average forward P/E of -2.69. For a more detailed relative valuation and DCF analysis to assess Orchestra Biomed Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.69
Current PE
-2.94
Overvalued PE
-0.18
Undervalued PE
-5.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.22
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.69
Undervalued EV/EBITDA
-3.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
55.72
Current PS
0.00
Overvalued PS
104.72
Undervalued PS
6.72
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 730.61% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 730.61% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

OBIO News & Events

Events Timeline

(ET)
2025-11-10
16:48:58
Orchestra BioMed Announces Q3 Earnings Per Share of 40 Cents, Below Consensus Estimate of 43 Cents
select
2025-10-28 (ET)
2025-10-28
08:17:56
Orchestra BioMed and Terumo Forge New $30M Agreements for Virtue SAB
select
2025-10-27 (ET)
2025-10-27
09:03:10
Orchestra BioMed Reports Initial Patient Enrollments in Virtue SAB Study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-27Newsfilter
Orchestra BioMed Grants 151,250 Stock Options to 12 New Employees
  • Employee Incentive Program: On November 24, 2025, Orchestra BioMed granted a total of 151,250 stock options to 12 new employees under the 2025 New Hire Inducement Plan, aimed at attracting talent and enhancing the company's competitive edge in the biomedical sector.
  • Vesting Structure: Each new employee will have 25% of their options vest on their first anniversary, with the remainder vesting quarterly over the next three years, which not only incentivizes long-term retention but also enhances team stability and execution capabilities.
  • Strategic Partnership Context: Orchestra BioMed's collaboration with Medtronic, a global medical device leader, accelerates the development of its AVIM therapy, expected to provide innovative solutions for uncontrolled hypertension patients, representing a multi-billion-dollar market opportunity.
  • Product Innovation Outlook: The company's Virtue SAB balloon system has received FDA Breakthrough Device Designation for treating atherosclerotic artery disease, highlighting its significance in the global medical market and the potential to significantly improve patient outcomes.
[object Object]
Preview
1.0
11-11Newsfilter
Orchestra BioMed to Attend Upcoming Conferences for Institutional Investors

  • Upcoming Investor Conferences: Orchestra BioMed will participate in the 2025 Jefferies London Healthcare Conference from November 17-20 and the Piper 37th Annual Healthcare Conference from December 2-4, hosting one-on-one meetings and a live fireside chat.

  • Company Overview: Orchestra BioMed focuses on accelerating high-impact biomedical technologies through partnerships with leading medical device companies, with flagship products AVIM Therapy and Virtue® Sirolimus AngioInfusion™ Balloon currently in pivotal clinical trials.

  • AVIM Therapy Details: AVIM Therapy is a bioelectronic treatment for hypertension, designed to be delivered via a firmware upgrade to pacemakers, and has received FDA Breakthrough Device Designation for patients with uncontrolled hypertension.

  • Virtue SAB Overview: The Virtue SAB is a novel drug delivery angioplasty balloon system aimed at treating atherosclerotic artery disease, also granted Breakthrough Device Designation by the FDA for specific coronary and peripheral artery conditions.

[object Object]
Preview
9.5
11-11NASDAQ.COM
Orchestra BioMed Holdings Reports Increased Loss in Q3

  • Third-Quarter Financial Performance: Orchestra BioMed Holdings, Inc. reported a net loss of $20.8 million or $0.40 per share for the third quarter, an increase from a net loss of $15.4 million or $0.41 per share in the same quarter of 2024.

  • Revenue Comparison: The company's revenue for the third quarter was $861 thousand, down from $987 thousand in the third quarter of 2024.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Orchestra Biomed Holdings Inc (OBIO) stock price today?

The current price of OBIO is 4.68 USD — it has decreased -3.7 % in the last trading day.

arrow icon

What is Orchestra Biomed Holdings Inc (OBIO)'s business?

Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

arrow icon

What is the price predicton of OBIO Stock?

Wall Street analysts forecast OBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OBIO is 12.50 USD with a low forecast of 10.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Orchestra Biomed Holdings Inc (OBIO)'s revenue for the last quarter?

Orchestra Biomed Holdings Inc revenue for the last quarter amounts to 861.00K USD, decreased -12.77 % YoY.

arrow icon

What is Orchestra Biomed Holdings Inc (OBIO)'s earnings per share (EPS) for the last quarter?

Orchestra Biomed Holdings Inc. EPS for the last quarter amounts to -0.40 USD, decreased -2.44 % YoY.

arrow icon

What changes have occurred in the market's expectations for Orchestra Biomed Holdings Inc (OBIO)'s fundamentals?

The market is revising Upward the revenue expectations for Orchestra BioMed Holdings, Inc. (OBIO) for FY2025, with the revenue forecasts being adjusted by 3.76% over the past three months. During the same period, the stock price has changed by 70.18%.
arrow icon

How many employees does Orchestra Biomed Holdings Inc (OBIO). have?

Orchestra Biomed Holdings Inc (OBIO) has 70 emplpoyees as of December 05 2025.

arrow icon

What is Orchestra Biomed Holdings Inc (OBIO) market cap?

Today OBIO has the market capitalization of 264.25M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free